Sintilimab plus sorafenib: a  novel regimen for hepatocellular carcinoma

Immunotherapy, Ahead of Print.

Source: Immunotherapy - October 19, 2021 Category: Allergy & Immunology Authors: Xuhong Liu Yong Yi Source Type: research